Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FR901228 (Romidepsin) in Refractory/Progressive Lung Cancer
NCT00020202Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of romidepsin in small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Jun 2000; status: completed.
02
Drugs
romidepsin
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00020202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020202.